The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen.

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers could be inflating drug costs in the U.S., in the latest and likely ...

The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

WASHINGTON, Jan 14 (Reuters) - The nation's three largest pharmacy ... FTC spokesperson told reporters in a press briefing, adding that the figure was "probably an underestimate." Pharmacy benefit ...

A giant healthcare company is suing the State of Minnesota over a state law that is supposed to protect small pharmacies in ...

Pharmacists in the Four-States say their livelihoods are at risk as major companies gain more control of the drug market. They're warning that Pharmacy Benefit Mangers, better known as PBMs, have an ...

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

After passing some regulations in 2024, Iowa state lawmakers are this year once again considering legislation that would further regulate pharmacy benefit managers — or PBMs.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.